Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259474 | 0.97 | CA12 (0.30) | CA12CA2CA3CA4CA6 | |
| SCHEMBL17383906 | 0.83 | KDM5A (0.32) | — | |
| SCHEMBL4257000 | 0.82 | CA12 (0.58) | CA12CA2CA3CA4CA6 | |
| SCHEMBL5110499 | 0.82 | CA12 (0.58) | CA12CA2CA3CA4CA6 | |
| SCHEMBL21538497 | 0.81 | — | — | |
| SCHEMBL14565654 | 0.78 | CA12 (0.53) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29582031 | 0.78 | CA12 (0.53) | CA12CA2CA3CA4CA6 | |
| SCHEMBL14191798 | 0.77 | MEN1 (0.41) | — | |
| SCHEMBL22952340 | 0.76 | CYP2C19 (0.31) | — | |
| SCHEMBL1948689 | 0.74 | CA12 (0.47) | CA12CA2CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550606-B2 | 9-cyano-substituted perylene-3,4-dicarboxylic acid monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-23 | — | — | US | disclosed |
| US-20090023937-A1 | 9-CYANO-SUBSTITUTED PERYLENE-3,4-DICARBOXYLIC ACID MONOIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-7446198-B2 | 9-Cyano-substituted perylene-3, 4-dicarboxylic monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20060229385-A1 | 9-Cyano-Substituted Perylene-3, 4-Dicarboxylic Monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023937-A1 | 9-CYANO-SUBSTITUTED PERYLENE-3,4-DICARBOXYLIC ACID MONOIMIDES | CA9, F9, CA13 | CA12 13/4885CA2 25/4885CA3 14/4885 |
| US-20060229385-A1 | 9-Cyano-Substituted Perylene-3, 4-Dicarboxylic Monoimides | CBR3, NR2C2, NR0B2 | CA12 839/4885CA2 1434/4885CA3 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.